Keith Edwards
Overview
Explore the profile of Keith Edwards including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Amatruda M, Petracca M, Wentling M, Inbar B, Castro K, Chen E, et al.
Sci Rep
. 2020 Sep;
10(1):15644.
PMID: 32973249
The disease course of patients with a confirmed diagnosis of primary progressive multiple sclerosis (PPMS) is uncertain. In an attempt to identify potential signaling pathways involved in the evolution of...
12.
Strakova P, Larmola T, Andres J, Ilola N, Launiainen P, Edwards K, et al.
Front Plant Sci
. 2020 Jun;
11:597.
PMID: 32508861
Evidence of plant root biomass and production in peatlands at the level of species or plant functional type (PFT) is needed for defining ecosystem functioning and predicting its future development....
13.
Wigger C, Leach A, Beissbarth J, Oguoma V, Lennox R, Nelson S, et al.
BMC Pharmacol Toxicol
. 2019 Jul;
20(1):46.
PMID: 31351491
Background: Chronic suppurative otitis media (CSOM) is a significant health issue affecting Aboriginal Australians. Long-term hearing loss can cause communication problems, educational disadvantage, and social isolation. Current standard treatment for...
14.
Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, et al.
J Comp Eff Res
. 2019 Feb;
8(5):305-316.
PMID: 30754997
Aim: Head-to-head clinical trials of teriflunomide (TFM) versus dimethyl fumarate (DMF) have not been conducted. Objectives: To compare the real-world effectiveness of TFM versus DMF. Methods: Anonymized data were collected...
15.
Cohan S, Edwards K, Lucas L, Gervasi-Follmar T, OConnor J, Siuta J, et al.
Mult Scler J Exp Transl Clin
. 2019 Feb;
5(1):2055217318824618.
PMID: 30729028
Background: Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies. Objective: To assess the efficacy of...
16.
Longbrake E, Kantor D, Pawate S, Bradshaw M, Geldern G, Chahin S, et al.
Neurol Clin Pract
. 2018 May;
8(2):102-107.
PMID: 29708225
Background: Fingolimod is a daily oral medication used to treat relapsing multiple sclerosis (MS). Clinicians often adopt less frequent dosing for patients with profound drug-induced lymphopenia or other adverse events....
17.
Younus Z, Vaughn C, Sanai S, Kavak K, Gupta S, Nadeem M, et al.
Int J MS Care
. 2017 Dec;
19(6):297-302.
PMID: 29270087
Background: Multiple sclerosis (MS) is a chronic, progressively disabling condition of the central nervous system. We sought to evaluate and compare mood states in patients with MS with increased disability...
18.
LaGanke C, Samkoff L, Edwards K, Jung Henson L, Repovic P, Lynch S, et al.
Neurol Neuroimmunol Neuroinflamm
. 2017 Jun;
4(4):e367.
PMID: 28642891
Objective: To evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX15/2503 in a randomized, single-dose, dose-escalation, double-blind, placebo-controlled study enrolling adult patients with MS. Methods: Single IV doses...
19.
Ralph A, Read C, Johnston V, Dassel J, Bycroft K, Mitchell A, et al.
Trials
. 2016 Jan;
17:51.
PMID: 26818484
Background: Rheumatic heart disease (RHD), caused by acute rheumatic fever (ARF), is a major health problem in Australian Aboriginal communities. Progress in controlling RHD requires improvements in the delivery of...
20.
Fox E, Edwards K, Burch G, Wynn D, LaGanke C, Crayton H, et al.
Mult Scler Relat Disord
. 2015 Aug;
3(5):607-19.
PMID: 26265273
Background: The Evaluate Patient OutComes (ClinicalTrials.gov Identifier: NCT01216072) study was conducted in North America to assess patient- and physician-reported treatment satisfaction in patients with relapsing multiple sclerosis (MS) who received...